Treatment Information

Back

Colon Cancer treatment details. Chemotherapy.

The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Houston, Texas
Treatments:ChemotherapyHospital:The University of Texas M.D. Anderson Cancer Center
Drugs:Journal:Link
Date:Jun 2004

Description:

Patients: This Phase II study involved 22 patients with metastatic colorectal cancer. All patients had been previously treated with 5-FU.

Treatment: Treatment consisted of the chemotherapy drug, capecitabine (xeloda).

Toxicity: Grade 3 toxicities included: hand-foot syndrome, diarrhea, fatigue, nausea, mucosal inflammation, abdominal pain, vomiting, and chest pain.

Results: No objective responses were observed. Median time to disesse progression was 64 days. Median survival time was 12.8 months.

Support: This study was supported in part by Hoffman-La Roche. Three of the studies authors receive funding from Roche Labs. Hoffman-La Roche markets capecitabine.

Correspondence: Paulo M. Hoff, MD




Back